Related references
Note: Only part of the references are listed.Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
Jedd D. Wolchok et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Personalized HLA typing leads to the discovery of novel HLA alleles and tumor-specific HLA variants
Irantzu Anzar et al.
HLA (2022)
Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up
Elin Aamdal et al.
INTERNATIONAL JOURNAL OF CANCER (2022)
Naturally Occurring Telomerase-Specific CD4 T-Cell Immunity in Melanoma
Charlee Nardin et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2022)
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials
Espen Basmo Ellingsen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
The interaction of CD4(+) helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response
Merav Cohen et al.
NATURE CANCER (2022)
Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma-Five-Year Follow Up of a Phase I/IIa Trial
Elin Aamdal et al.
FRONTIERS IN IMMUNOLOGY (2021)
Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential
Espen Basmo Ellingsen et al.
FRONTIERS IN IMMUNOLOGY (2021)
Therapeutic cancer vaccines
Mansi Saxena et al.
NATURE REVIEWS CANCER (2021)
Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inibitor Response
Meagan Montesion et al.
CANCER DISCOVERY (2021)
Artificial intelligence predicts the immunogenic landscape of SARS-CoV-2 leading to universal blueprints for vaccine designs
Brandon Malone et al.
SCIENTIFIC REPORTS (2020)
Genomic correlates of response to immune checkpoint blockade
Tanya E. Keenan et al.
NATURE MEDICINE (2019)
WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs
Yuxing Liao et al.
NUCLEIC ACIDS RESEARCH (2019)
Distinct prognostic value of circulating anti-telomerase CD4+ Th1 immunity and exhausted PD-1+/TIM-3+ T cells in lung
Caroline Laheurte et al.
BRITISH JOURNAL OF CANCER (2019)
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert et al.
LANCET ONCOLOGY (2019)
T cell receptor next-generation sequencing reveals cancer-associated repertoire metrics and reconstitution after chemotherapy in patients with hematological and solid tumors
Donjete Simnica et al.
ONCOIMMUNOLOGY (2019)
High-Throughput Immunogenetics Reveals a Lack of Physiological T Cell Clusters in Patients With Autoimmune Cytopenias
Donjete Simnica et al.
FRONTIERS IN IMMUNOLOGY (2019)
Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Jong Yeob Kim et al.
CANCERS (2019)
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
Anu Sharma et al.
CLINICAL CANCER RESEARCH (2019)
Mechanisms of resistance to immune checkpoint inhibitors
Russell W. Jenkins et al.
BRITISH JOURNAL OF CANCER (2018)
Essential roles of telomerase reverse transcriptase hTERT in cancer stemness and metastasis
Ricarda Hannen et al.
FEBS LETTERS (2018)
The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma
Anton Uryvaev et al.
MEDICAL ONCOLOGY (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
CD4+ T cell help in cancer immunology and immunotherapy
Jannie Borst et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Prognostic impact and concordance of TERT promoter mutation and protein expression in matched primary and metastatic cutaneous melanoma
Emilia Hugdahl et al.
BRITISH JOURNAL OF CANCER (2018)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas
Tareq A. Juratli et al.
ONCOTARGET (2017)
Overview of methodologies for T-cell receptor repertoire analysis
Elisa Rosati et al.
BMC BIOTECHNOLOGY (2017)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan et al.
SCIENCE (2016)
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Sebastian Kreiter et al.
NATURE (2015)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
Telomerase is an independent prognostic marker of overall survival in patients with colorectal cancer
R. Bertorelle et al.
BRITISH JOURNAL OF CANCER (2013)
Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells
Z. Liu et al.
ONCOGENE (2013)
Highly Recurrent TERT Promoter Mutations in Human Melanoma
Franklin W. Huang et al.
SCIENCE (2013)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Altered Telomeres in Tumors with ATRX and DAXX Mutations
Christopher M. Heaphy et al.
SCIENCE (2011)
edgeR: a Bioconductor package for differential expression analysis of digital gene expression data
Mark D. Robinson et al.
BIOINFORMATICS (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Chromosomal imbalances in primary and metastatic melanomas: over-representation of essential telomerase genes
C Pirker et al.
MELANOMA RESEARCH (2003)
Share Paper
